Hanmi Pharmaceutical has presented two drug candidates employing its proprietary Lapscovery platform technology at the European Association for the Study of Diabetes.
The two therapies in development are a triple agonist for non-alcoholic fatty liver disease and Parkinson’s, and a glucagon analog for treating congenital hyperinsulinism.
Both drugs employ Hanmi’s Lapscovery — short for Long Acting Protein and Peptide Discovery — which extends the life of a biologic drug within the body, extending its efficacy and potency.
 |
Hanmi Pharmaceutical introduces its new drug candidates employing its Lapscovery technology at the EASD conference in Lisbon. (Hanmi Pharmaceutical) |
Hanmi presented the animal testing results of the two drugs and their efficacy during this year’s EASD conference in Lisbon, Portugal earlier this month.
A triple agonist is a biologic agent that simultaneously activates glucagon, an energy metabolism booster, as well as GLP-1 and GIP, which aid insulin uptake and release.
A glucagon analog instigates glucose synthesis by acting as a glucagon inhibitor. It has shown an ability to elevate blood sugar levels, suggesting it can become a potential treatment for hyperinsulinism, Hanmi said.
Both drugs have been developed as drugs requiring a single injection per week, according to the Korean drugmaker. Looking ahead, it plans to continue expanding the application of its Lapscovery technology into new disease areas.
By Sohn Ji-young (
jys@heraldcorp.com)
